Distinctions and Parallels Among TRK Inhibitors

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.

Related Videos

October 23, 2018

Dealing with Issues of Obtaining Sufficient Tissue in Performing Biomarker Testing

Drs. Roy Herbst and David Rimm review some of the problems associated with obtaining enough tissue to perform biomarker testing, the need to triage tissue to ensure that standard of care tests are completed, and the potential role of liquid biopsies

November 19, 2014

Affordable High Quality Care for Patients

Ken Schaecher, MD, presents his own personal opinion on the multiple barriers to affordable high quality care for cancer patients. Supported through funding from Incyte